Long-Term Development of Muscular Dystrophy Outcome Assessments
Part of paid clinical trials in Richmond, Virginia.
- Sponsor
- Virginia Commonwealth University
- Study ID
- NCT05989620
- Status
- Recruiting
Conditions
- LGMD1B
- LGMD1C
- LGMD1D
- LGMD1E
- LGMD1F
- LGMD1G
- LGMD1H
- LGMD2A
- LGMD2B
- LGMD2C
- LGMD2D
- LGMD2E
- LGMD2F
- LGMD2G
- LGMD2I
- LGMD2J
- LGMD2K
- LGMD2L
- LGMD2M
- LGMD2N
- LGMD2O
- LGMD2P
- LGMD2Q
- LGMD2S
- LGMD2T
- LGMD2U
- LGMD2W
- LGMD2X
- LGMD2Y
Eligibility Criteria
- Sex
- ALL
- Age
- 6 Years - 50 Years
- Healthy Volunteers
- Not accepted
Study Details
This is a 24-month, observational study of up to 1000 participants with Limb Girdle Muscular Dystrophy (LGMD), Myotonic Dystrophy Type 2 (DM2), and late onset Pompe disease (LOPD).
Key Dates
- Start date
- Oct 18, 2023
- Status verified
- Nov 2025
- Primary completion
- Oct 1, 2028
- Completion
- May 1, 2029
Study Design
- Enrollment
- 1,000 participants (estimated)
Arms
- Arm: LGMD, DM2, LOPD
Primary Outcome Measure
To explore the suitability and feasibility of the North Star Assessment for LGMD (NSAD) in the muscular dystrophies [ Time Frame: Baseline to 24 months ]
Central Contacts
- Jennifer Raymond804-828-6318
- Ruby Langeslay
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Virginia Commonwealth University | Richmond | Virginia | 23298 | Levi Headrick Nicholas Johnson, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Richmond, VA
By research site
Related Studies
- A Study to Evaluate the Safety of AB-1003 (Previously LION-101) in Subjects With Genetic Confirmation of LGMD2I/R9 (Part1)PHASE1/PHASE2 · Recruiting · AskBio Inc · Irvine, California